Half of Cambodia's population is at risk of acquiring malaria (1). In response to the emergence 34 of ART-resistant P. falciparum in multiple provinces (2, 3)(4), Cambodia has developed a 35 strategic plan to combat malaria (5). Its goals are to eliminate ART-resistant P. falciparum by 36 2015, P. falciparum malaria deaths by 2020, and all forms of malaria (including P. vivax) by 37
2025. This approach recognizes that as control measures become more effective, P. vivax will 38 cause an increasingly greater proportion of malaria cases. This is because P. vivax hypnozoites 39 survive blood-stage antimalarials, are not routinely treated with primaquine due to the 14% 40 prevalence of G6PD deficiency in Cambodia (6), and thus can cause relapsing malaria (7). 41 42 CQ is the frontline treatment for P. vivax malaria in areas where resistance has not been 43 reported, while ACTs are the recommended treatments in areas where resistance is prevalent 44 (8) -especially where ACTs are used as frontline treatments for P. falciparum malaria (9). CQ-45 resistant P. vivax malaria was first described in Papua New Guinea in 1989 (10) and has since 46 been documented in parts of Southeast Asia and the . Only two studies have 47 Pursat. Of these, 1518 patients had a negative rapid diagnostic test (RDT, First Response, 60 pLDH/HRP2 Combo, Premier Medical Corp. Ltd., India) for malaria parasitemia. Giemsa-stained 61 smears of RDT-positive blood samples showed that 178 patients had P. falciparum infection, 42 62 had mixed P. falciparum and P. vivax infections, and 191 had P. vivax malaria (mono-infection, 63 any parasite density, and axillary temperature ≥37.5 o C or history of fever in the previous 2 d). 64
Of these 191 patients, 87 met additional inclusion criteria: age >2 years, hematocrit ≥25%, and 65 willingness to complete treatment in hospital and receive follow-up visits at home. Patients 66 were excluded if they were pregnant or used any antimalarial in the previous 2 months. No 67 patient had signs of severe malaria, malnutrition, concomitant or chronic disease, or reported 68 hypersensitivity to CQ. Adult patients or the parents of children gave written informed consent. Ranbaxy Pharmaceuticals, FL) 10 mg/kg at 0 and 24 h, and 5 mg/kg at 48 h. We specifically 87 withheld primaquine therapy to avoid inducing hemolytic anemias in patients with G6PD 88 deficiency. Axillary temperatures were measured and parasite densities estimated as described 89
(2) every 24 h until asexual parasitemia was undetectable (i.e., no asexual parasites observed 90 (Figure 1A) . Gametocyte densities also dropped at 24 h (median 349/µl to 16/µl, 96.4% 94 reduction, P<0.0001) (Figure 1B) . The proportions of patients with asexual parasitemia at 0, 24, 95 48, and 72 h were 100, 79.3, 4.60, and 0%, with gametocytemia were 85.0, 58.6, 11.5, and 96 2.30%, and with fever (≥37.5 o C) were 86.2, 21.8, and 0%. Nearly all (90.8%) patients, however, 97 were given paracetamol for fever. 98
99
Patients were followed up on days 7, 14, 21, and 28. At each visit, axillary temperature was 100 measured and blood smears examined for recurrent malaria parasitemia. Data from 3 patients 101 who were lost to follow-up were not analyzed, but data from 8 patients who missed 1, 2, or 3 102 follow-up visits were analyzed since all were seen on day 28 and none reported fever since 103 discharge. Among 84 patients with adequate follow-up, 1 had asymptomatic P. vivax 104 parasitemia (60/µl) on day 28, 1 had asymptomatic P. falciparum parasitemia (402/µl) on day 105 28, and 1 had P. falciparum malaria (16149/µl, 40.1°C) on day 21. Thus, the cumulative risk of 106 recurrent P. vivax parasitemia at 28 d was 1.2% (1/84). Whether this recurrent parasitemia 107 episode was due to relapse, recrudescence, or reinfection has not been determined. 108
109
In Pursat in 2012, our use of RDTs and expert microscopy accurately detected P. vivax mono-110 infections, which were treated effectively with CQ. The lingering presence of CQ at levels above 111 the minimally effective concentration likely prevented the detection of relapse infections, 112 which have a high probability of occurring within 28 d. In other provinces where ART-resistant 113 6 P. falciparum is prevalent, programs that accurately diagnose and monitor the clearance of P. 114 vivax mono-infections may help to minimize the use of ACTs. Since the proportion of patients 115
with detectable parasitemia at 72 h was 0%, an increase in this proportion may be a useful 116 phenotypic marker for emerging CQ resistance in Pursat. "Day 3 positivity" rates, which 117 estimate this proportion, have previously been associated with CQ resistance in Preah Vihear 118 (3.3%) and Ratanakiri (4.3%), and with CQ sensitivity in Pailin (0%) (16). Baseline data for each 119 province could be useful to future surveillance and elimination programs in Cambodia. Nearly 120 all patients had undetectable gametocytemia at 72 h, suggesting that CQ also remains effective 121 in reducing P. vivax transmission in Pursat. 
